Good morning. My name is Janie and I will be your conference operator today. I would like to welcome everyone to the Insperity Second Quarter 2023 Earnings Conference Call. Currently, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded. At this time, I would like to introduce today's speakers. Joining us, are Paul Sarvadi, Chairman of the Board and Chief Executive Officer; and Douglas Sharp, Executive Vice President of Finance, Chief Financial Officer and Treasurer. At this time, I'd like to turn the call over to Douglas Sharp. Mr. Sharp, please go ahead.

Thank you. We appreciate you joining us. Let me begin by outlining our plan for this morning's call. First, I'm going to discuss the details behind our second quarter 2023 financial results. Paul will then comment on the quarter and our plan over the remainder of the year. I will return to provide our financial guidance for the third quarter and an update to the full year guidance. And then we will end the call with a question-and-answer session. Now before we begin, I would like to remind you that Mr. Sarvadi or I, may make forward-looking statements during today's call, which are subject to risks, uncertainties and assumptions. In addition, some of our discussion may include non-GAAP financial measures. For more detailed discussions of the risks and uncertainties that could cause actual results to differ materially from any forward-looking statements and reconciliations of non-GAAP financial measures, please see the company's public filings, including the Form 8-K filed today, which are on our website. Now, let's discuss our second quarter ‘23 financial results in which we effectively executed on our plan and sales, service, pricing in other areas of the business, however, experienced the shortfall from our forecasted earnings due to substantially higher healthcare costs. We reported adjusted EPS of $0.64 and adjusted EBITDA of $51 million for the quarter. As for our growth metric, the average number of paid worksite employees increased by 7.2% over Q2 of 2022, which was just below the midpoint of our guidance as net hiring by our clients came in slightly lower than expected. Worksite employees paid from a combination of sales and client retention came in on target. Moving to gross profit, we continue to achieve pricing above target levels. And we combined with our workers compensation program, payroll tax area, and traditional…

Thank you, Doug, and thank you all for joining our call. Today, I'd like to provide comments on the following three topics. First, I'll comment on the second quarter excellent execution and the results across key long-term performance drivers in our business. Second, I'll discuss how Insperity is positioned to capitalize on our vast market opportunity with a focus on the future of the workplace, and the corresponding changes needs, changing needs in our target market. I'll finish with comments on the outlook for the company into next year and beyond despite the unexpected large healthcare claims in the recent quarter. Our most important key drivers for long- term success and growth and profitability more within our control, our new sales, pricing, client service and retention. All these areas were strong in Q2 and contribute toward a positive outlook for the future. Our workforce optimization book sales were solid driven by an outstanding effort in our mid-market business performance consultant team. This team experienced one of their strongest quarters in history in book sales and both deal count and worksite employees sold. In addition to substantial book sales, excellent progress was made by our BPAs driving sales activity, which was a priority coming into the quarter. Our 15% higher number of BPAs increase discovery calls nearly 30% over Q2 of last year, making our prospective client pipeline significantly stronger as we go into the second half of the year. One of the other highlights of the quarter was workforce acceleration or WX, continuing to gain traction across the sales organization, and coming in well above budget and booked sales. One of the reasons this is exciting is the opportunity to test one of our assumptions regarding WX. At this level of WX adoption and incentives, and a large number of…

Thanks Paul. Now, let me provide our guidance for Q3 and an update for the full year 2023. Our updated earnings guidance includes assumptions around a possible range of outcomes and our benefit costs over the remainder of the year, outside of this area, we continue to expect favorable trends in our pricing and other areas of gross profit and are forecasting slightly lower paid worksite employees and operating expenses. As for the details, we are now forecasting 6.5% to 7% worksite employee growth for the full year 2023, slightly lower than our previous guidance and a tighter rein since we are now more than halfway through the year. The lower growth outlook is primarily a result of Q2’s average paid worksite employees coming in a little light due to lower hiring in our client base. And an assumption that this lower hiring continues over the remainder of the year. As for Q3, we are forecasting year-over-year worksite employee growth of 4% to 4.5%. Now this is lower than our full year growth forecast due to our assumption of significantly less hiring in Q3 of 2023 compared to Q3 of 2022. However, this guidance reflects continuing sequential worksite employee growth over the remaining two quarters of 2023 and improving year-over-year growth in Q4. We have revised our earnings guidance based upon our results through first half 2023 in our updated outlook for worksite employee growth and the range of expectations around our benefit costs as previously discussed. So after putting together the pieces, we're now forecasting full year 2023 adjusted EBITDA in a range of $300 million to $350 million and adjusted EPS in the range of $4.35 to $5.32. As for Q3 earnings, we are forecasting adjusted EBITDA in a range of $57 million to $81 million and adjusted EPS from $0.69 to $1.14. Now, at this time, I'd like to open up the call for questions.

[Operator Instructions] Your first question is coming from Andrew Nicholas of William Blair.

Thank you and good morning. I wanted to ask on the benefits cost side first, I was hoping you could provide a little bit more color on the benefits cost trend, particularly on the $750,000 plus side. Is there anything to pinpoint in terms of the underwriting approach or the risk management approach that would help to explain that or is it just some noise? And then, I guess maybe the bigger picture question is do quarters like this change your appetite for risk on the healthcare side? Or any kind of long-term ramifications to this kind of quarter? Thank you.

Yes, I think when you look at a little bit more of the detail behind the costs, obviously, we investigate them, investigated some of the detailed claims data that was provided from our health care carrier very diligently, I think one thing that came out of that was that there was not a higher concentration of large claims from new clients, which would indicate that through our fall selling season and our year and renewal, that is not the situation where there has been adverse client selection, that's obviously one of the first things that you want to rule out. When you look at the types of claims. It's really across the board as far as the $750,000 and above, you've got some cancer, you've got some heart attacks, you've got some accidents. And so it's really varied and diversified over as far as the nature of the type of claims. And so I think it was, from what we can see thus far, yes, we did have a claim, a period of large claim activity. It has happened in our history. But I think we still feel particularly when you look at Paul's comments with respect to over the long term and the five year compounded rates, that we are still managing the healthcare costs trends, even with the forecasted higher costs over the remainder of the year, within a range of tolerated tolerable range, and really within a range where our pricing with been above target recently, and maybe some adjustments and some adjustment to that we feel like the matching of pricing costs is still in play.

So let me address the second half of that question about the kind of appetite for risk. Because I think there's two different ways you have to look at it. First of all, we are comfortable with the way we have structured our program to align price and cost over the long term. And we know that it provides advantage to grow the business and it provides a more profitable long-term structure. But at the same time, we have shared out like when we have a large claim quarter like this, and as you know, when we did this in 2019, we did purchase a coverage limit on individuals at the million dollar level. We also we'll continue to look and evaluate that as this year goes by. We've quoted lowered limits before sure we'll take a look at that, like we do every year. And I would just say also that we, on an ongoing basis, look at other possibilities, to take out some of the volatility that relates to this type of quarter, and how that affects us in the public markets. So we continue to pursue those things. So I would say our appetite to, we still want to run the business this way, but certainly if we can find other ways to reduce the volatility that's caused by these occasions, we'll continue to pursue that.

That's helpful. Thanks to you both. I guess for my follow up question, I wanted to ask on capital allocation, and maybe the capacity you have for repurchases in 2023, especially in light of the increased authorization, and I think, Doug, your comments on your intention to be a bit more aggressive there, can you just flush out the type of capacity you have this year to put back into buying the stock? Thank you?

Well, I think you see from the increased authorization of 2 million shares, it would give you some indication as to where the board is currently feeling with respect to repurchase authorization, which would indicate a higher level than what we have done typically, and but even look at over the course of our history, we've always been a big purchaser of shares. I think if you go back to the 2019 events, where we had some quarters of high elevated large claim activity, we were quite aggressive because we felt that over the long term, the business model remained very much intact. I think we obviously feel very confident in that today. So with the increased authorization, it does allow us to be more aggressive, should opportunities present themselves coming off of this quarters activity, again, strong confidence that our long-term plans are still in place, and still reasonable targets for us.

Your next question is coming from Tobey Sommer from Truist Securities.

Thanks. I was wondering if you could share with us your expectations and what you're hearing from your healthcare provider, about whether the higher healthcare expense level may continue into 2024. I think it's been a theme and concern that people had sort of in the post pandemic era. Thanks.

Yes, I think we do continue these conversations on an ongoing basis. And, Tobey, as you heard from our discussion here, we did go ahead and build in just a higher pharmacy trend, because there's things in there that same, they're likely -- more likely to continue than to be a short term bubble. So we do continue to monitor those things. I think it's different from this, the large claim component, however, since we had a difficult, long, difficult period 2019 that covered multiple quarters, we've just used wider range of the expectation for this year. But we, in the conversation with our advisors and outside the company. We think we’re properly managing and aligning our costs and price with the underlying trends.

Thanks, Paul. And for my follow up, I’ll make it two prongs, if I could so. The mid-year price hike you talked about 1.5%, is that applicable to all clients? Or is that sort of a new and renewing client only? And then maybe you could talk about and dig into your experience with BPA retention, and maybe talk about something a little more exciting on the sales front away from the benefits? Thanks.

Sure. So we, when we look at, remember where -- we are looking at pricing every day in our operation, based on the trends that are that we're seeing, and we're pricing new and renewing business every day. And so when we talk about raising that adding another 1% to 1.5% that began at immediately when we decided that and that adds to the typical trend increases, we've been building into clients, clients typically get an increase from us, it varies based on their experience with us. But generally speaking, customers will get an increase in the high single digits, some will get double digits, but most of the time, it's on average, I would say in high single digits. And then they will make their own decisions on how to lower that cost by plan selection, or how they might share costs with employees are other issues that they'll look at. So what we're saying now is, we'll continue to drive that higher than the average it's been. But it appears to us to be very much in line with what is going on in the marketplace at large. So we're not in a position where we've got to raise price considerably. And in response to what we see going on, we think we're comfortable with where we are, and what we're able to pass on. And as you can see, we've just come off of a year and a half of really strong pricing success with our client base. So we're very comfortable with that going forward. So now on the exciting part, on the growth side, yes, I'm very excited about really everything we're doing in our organization around the core business, and the incentives that we've changed to direct behavior at the appropriate things at the appropriate time. Also the WX element, that we also have set it in such a way that we're seeing the lower turnover year-to-date. And that has a dramatic potential effect. And then of course, the other factor that I always want to focus on is how successful we were in mid-market. And we are building that team, and building that pipeline for more consistent and predictable growth on the mid-market front. So all three of those pieces together, really point to positive growth outlook for the company. Even though we've been in a period of time when growth in the business is below the double digit number, we're still have had the highest growth rate in the industry. But I think as these things really take effect, there's this long-term potential for improved sales efficiency, from less turnover. And in addition to that, it's also lower cost, dramatically lower cost when you have lower turnover. So that kind of has a double dip positive effect. And we're excited about where we are on that front. Still a lot of work to do. But we're really poised for an excellent second half.

Your next question is coming from Mark Marcon of Baird.

Thank you. Got a couple of questions. The first one just basically relates, again, to a little bit more detail with regards to the higher healthcare book claims. And what I'm wondering specifically is can you talk a little bit more about what's going on the pharmaceutical side? Which seems like it will be an ongoing trend. And then on the larger claims, did you find that it's -- that you had more severe incidents? Or is there also some inflation for some higher incidence? In other words, is treating the same type of cancer, significantly more expensive today than it used to be? Or are heart attacks more expensive than they used to be? Obviously, labor costs are going up within hospital system. So I'm wondering if that's part of what we're seeing?

Well, I think on that front, that's a good point. And we do monitor exactly that. And that's generally more in the typical year-to-year trend numbers. And we work of course with our outside advisors, and of course with our carriers to monitor those things. But what we're really talking about this quarter, I don't think that factor is an underlying factor all the time and not that different this quarter. But on the pharmacy side, I think most people have heard and as you see in the marketplace, a lot of discussion about various drugs that are being used especially more recently on the weight loss front, some of the diabetes drugs and the drugs that maybe weren't originally designed for that, but are being used that way more of a fad type thing. And I think that's that may weighing also, because there are some long term effects that are not positive for people. But it takes time for that to run through. And so there's also I think, an increase in behavioral health needs. And that is also a factor that if you think about being two years into a period of high inflation and kind of the squeeze in the wallet for a lot of people that has a mental and nervous effect that has a behavioral health cost effect. And so those are things that we kind of saw underlying here, and said, look that that most important to build in, as we see it. So we've done that. And like I said, we've done stuff on the pricing side, to make sure that's all aligned, going forward.

Great. Then with regards to implementing a modest price increase which can be mitigated to a certain effect by the behaviors of the clients, what sort of impact would that have on sales? And then offsetting that to what extent Paul, can you accelerate WX to even greater effect. And take out some of the healthcare risks from the initial pricing discussion.

Yes, that's good. We definitely on the WX front, one of the advantages, of course of growing that business is it's not, there is no medical risk in that business. So we do see that as a nice enhancement. And we are intending to drive that considerably as time goes forward, it makes sense to do that. And we are, what's happening right now is the sales team is really getting on board, we incented their effort to close WX business. And that has such so many strong effects. They're adding a client base of their own, that can upgrade to WO as time goes on. And they're feeling more successful early in their tenure. And that's what's lowering the turnover. So, we just see a lot of advantages for WX and we are definitely moving that ball forward and expect that it can be much larger. There are other things that we're doing there that deal with some of these changes in the workplace issues that I was discussing, for example, access to wages and things of that nature, other tools that can be provided to employees for wellness, we're doing that both in WX and WO on the financial wellness and other types of services that employees are demanding more and more kind of post COVID. So we are moving ahead there. And I think looking forward to some dramatic success in WX.

Tobey, I think your other question with respect to the pricing adjustments that we're going to be making on the healthcare side, as we mentioned earlier, the good news is we've been above our targets on the medical pricing allocations over the course of this year, and when we look at our forecasts, and assuming a wide range and that some of this large claim activity continues. We're looking at making incremental pricing changes in the range of 1% to 1.5%. And looking out there in the marketplace, it's very much in line with the marketplace trends. So we don't think that our pricing is going to be outside of the marketplace trends, and will be very consistent and shouldn't put at a disadvantage.

Your next question is coming from Jeff Martin of ROTH Capital Partners.

Thank you. Good morning. Doug, wanted to get a sense when you think the potential price increases for the benefit cost allocation may be fully implemented. Is that early next year, or is that going to be sooner than that?

Yes, a significant chunk of it happens through the year end transition and then they will continue on through the first quarter or so of the year. But that's just that one -- that's the increase component. And we we've been having strong pricing increases that are flowing in every month.

Got it. Okay. And then on the new initiative in terms of helping small businesses position for the current environment and attracting and retaining employees, is that an added component in terms of an additional service charge? Or is that lumped in with the workforce optimization product?

I'm sorry, can you repeat that for me?

I was just curious if that's, if that new service offering for small businesses where you hired Kathy Johnson, are you brought, you elevated her to lead that effort? Is that going to be an offering that you specifically charge for as part of workforce optimization, or is that built into the product itself.

So that's good that you bring that up, because what this strategic planning and development group is all about, is carefully evaluating any new things that are offered to determine the appropriate structure for that addition. And so there will be things that will be charged for because they're outside of sale, it’s no for us, we don't want to just keep adding to the bundle, so to speak. And there's certain services or products that people want to own to have outside of that bundle. So we'll be looking at a variety of things on every product service, every improvement that we're going to make to that group. We'll be looking at those as financial investments and looking for the return on those investments. Thank you very much. We have reached the end of our question-and-answer session. I will now turn the call over to Mr. Sarvadi for any closing remarks.

Once again, we do want to thank everyone for participating today. And we look forward to strong second half of continued to focus on our growth into the future and continuing our strong second year in our five year plan. So thank you once again for being a part of this today. And we look forward to talking to you next quarter. Thank you.

Thank you, everybody. This does conclude today's conference call. You may disconnect your lines at this time. And have a wonderful day. Thank you for your participation. Goodbye.